Knight Therapeutics Inc (TSE:GUD) – Cormark upped their FY2016 earnings estimates for Knight Therapeutics in a note issued to investors on Friday. Cormark analyst D. Novak now forecasts that the brokerage will earn $0.11 per share for the year, up from their prior estimate of $0.10. Cormark also issued estimates for Knight Therapeutics’ Q4 2016 earnings at $0.03 EPS.

GUD has been the topic of a number of other research reports. Scotiabank reaffirmed an “outperform” rating and set a C$9.50 price target on shares of Knight Therapeutics in a research note on Monday, July 18th. CIBC upped their price target on shares of Knight Therapeutics from C$9.50 to C$9.80 in a research note on Friday. Bloom Burton reaffirmed an “accumulate” rating on shares of Knight Therapeutics in a research note on Thursday. Finally, TD Securities upped their price target on shares of Knight Therapeutics from C$10.00 to C$11.00 and gave the company a “buy” rating in a research note on Friday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of C$9.83.

Knight Therapeutics (TSE:GUD) opened at 9.64 on Monday. The stock has a market capitalization of $1.28 billion and a PE ratio of 59.88. The company’s 50-day moving average is $9.19 and its 200-day moving average is $8.62. Knight Therapeutics has a 12 month low of $5.89 and a 12 month high of $9.82.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.

Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.